Results 181 to 190 of about 103,104 (359)

772 SERUM HEPATITIS B SURFACE ANTIGEN LEVELS DURING FIVE YEARS ENTECAVIR THERAPY IN ASIAN CHRONIC HEPATITIS B PATIENTS

, 2013
Wai‐Kay Seto, Ying-lee Lam, J. Fung, Danny Wong, Ching–Lung Lai, MF Yuen   +5 more
openalex   +1 more source

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy

, 2022
Claudia Hawkins, Minhee Kang, Debika Bhattacharya, Gavin Cloherty, Mary Kuhns, Roy Matining, Chloe Thio, Wadzanai Samaneka, Lameck Chinula, Nyirenda Mulinda, Sharlaa Badal-Faesen, Patcharaphan Sugandhavesa, Javier Lama, Simani Gaseitsiwe, Vera Holzmayer, Mark Anderson, Robert Murphy, Marion Peters, Claudia Hawkins   +18 more
openalex   +2 more sources

Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression

Alimentary Pharmacology &Therapeutics, EarlyView.
In‐depth multiomics analyses revealed that the gut microbiota in patients with CPH is dysbiotic. Altered gut microbiota plays an important role in the progression of CPH and affects the host's arginine metabolism to promote arginine biosynthesis. The pro‐inflammatory effects of certain gut bacteria induce iNOS expression, which together act on the ...
Qun Zhang, Jinghua Cui, Yixin Hou, Lining Guo, Hai Li, Guiqin Zhou, Xiaojing Wang, Bingbing Zhu, Ke Shi, Yi Zhang, Yufei Bi, Yanqiu Li, Lina Sun, Ying Feng, Jing Yuan, Xianbo Wang   +15 more
wiley   +1 more source

Yeast vaccine production platform for human and animal infectious diseases. [PDF]

Front Immunol
Ramos-Vega A, Monreal-Escalante E, Bañuelos-Hernández B, Angulo M, Trujillo E, Angulo C.   +5 more
europepmc   +1 more source

Unstable Recompensation: An Intermediate Subtype in Patients With HBV‐Related Decompensated Cirrhosis

Alimentary Pharmacology &Therapeutics, EarlyView.
Recompensation is a heterogeneous and dynamic state in HBV‐related decompensated cirrhosis; The prognosis for patients with unstable recompensation was found to be worse compared to those with stable recompensation, but still better than patients without recompensation; Subclassification of recompensation has significant implications for prognosis and ...
Shuai Xia, Zhiying He, Xiaoning Wu, Zhongjie Hu, Chunqing Zhang, Yanqin Hao, Yongfeng Yang, Yan Huang, Wei Rao, Xiaoqian Xu, Xinyu Zhao, Jialing Zhou, Yameng Sun, Shuyan Chen, Luqi Tang, Xiaojuan Ou, Xinyan Zhao, Jidong Jia, Bingqiong Wang, Hong You   +19 more
wiley   +1 more source

Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen‐positive hepatocellular carcinoma: a comparison with chronic carriers [PDF]

, 2007
Myron J. Tong, Lawrence M. Blatt, Jia‐Horng Kao, Jason T. Cheng, William Corey   +4 more
openalex   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

A novel monoclonal antibody targeting a conserved inner region of the hepatitis B virus envelope enables broad detection of immune escape variants. [PDF]

Virus Res
Chen Y, Zhang X, Ashuo A, Fang Z, Song W, Liu J, Chen J, Li Y, Yuan Z.   +8 more
europepmc   +1 more source

Hepatitis B Virus Surface Antigen Variants Clustered Within Immune Epitopes in Chronic Hepatitis B Carriers from Hormozgan Province, South of Iran [PDF]

, 2010
Mehdi Norouzi, Seyed A. Ghorashi, Behrooz Ataei, Majid Yaran, Reza Malekzadeh, Seyed Moayyed, Shiva Ghamari, Alireza Namazi, Ramin Rahimnia, Abolfazl Khedive, Seyed Mohammad Jazayeri   +10 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source